Editas Medicine(CH:8EM)
CHF 2.05-0.18 (-0.73%)
CH:8EM
Editas Medicine stock forecast
CHF 2.05
At close:-0.18 (-0.73%)
Editas Medicine (8EM) Stock Forecast & Price Target
1 Followers
8EM Analyst Ratings
Strong Buy
4Buy1Hold0Sell
Based on 5 analysts giving stock ratings to Editas Medicine in the past 3 months
8EM Stock 12 Month Forecast
Average Price Target
CHF 4.26▲(108.21% Upside)Based on 5 Wall Street analysts offering 12 month price targets for Editas Medicine in the last 3 months. The average price target is CHF 4.26 with a high forecast of CHF 4.92 and a low forecast of CHF 3.28. The average price target represents a 108.21% change from the last price of CHF 2.05.
Past 12 Months12 Month ForecastJan2026Oct2026
HighCHF 4.92
AverageCHF 4.26
LowCHF 3.28
Highest Price TargetHighestCHF 4.92Average Price TargetCHF 4.26Lowest Price TargetLowestCHF 3.28
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
| Mitchell Kapoor | H.C. Wainwright | CHF 4.10 | buy | 100.20%Upside | Reiterated | 11/10/26 | ||
| Yanan Zhu | Wells Fargo | CHF 4.92 | buy | 140.24%Upside | Reiterated | 11/09/26 | ||
| Luca Issi | RBC Capital | CHF 3.28 | hold | 60.16%Upside | Reiterated | 11/09/26 | ||
| Debjit Chattopadhyay | Guggenheim | CHF 4.10 | buy | 100.20%Upside | Upgraded | 09/23/26 | ||
| Rick Bienkowski | Ladenburg Thalmann & Co. | CHF 4.92 | buy | 140.24%Upside | Initiated | 08/18/26 | ||
| Alec Stranahan | Bank of America Securities | ― | sell | ― | Reiterated | 08/07/26 | ||
| Boris Peaker | JonesTrading | CHF 6.56 | buy | 220.32%Upside | Reiterated | 08/05/26 | ||
| Phil Nadeau | TD Cowen | ― | buy | ― | Reiterated | 08/05/26 | ||
| Jonathan Miller | Evercore ISI | CHF 12.29 | buy | 500.61%Upside | Reiterated | 05/27/26 | ||
| Geulah Livshits | Chardan Capital | CHF 3.28 | buy | 60.16%Upside | Reiterated | 05/05/26 | ||
| Joon Lee | UBS | ― | hold | ― | Reiterated | 03/17/26 | ||
| Brian Cheng | J.P. Morgan | ― | sell | ― | Reiterated | 03/13/26 | ||
| William Maughan | Clear Street | CHF 3.77 | buy | 84.19%Upside | Reiterated | 03/10/26 | ||
| Gena Wang | Barclays | CHF 2.46 | hold | 20.12%Upside | Reiterated | 11/11/25 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| Mitchell KapoorH.C. Wainwright | BuyReiteratedCHF 4.10 | 11/10/26 | 100.20%Upside | ||
| Yanan ZhuWells Fargo | BuyReiteratedCHF 4.92 | 11/09/26 | 140.24%Upside | ||
| Luca IssiRBC Capital | HoldReiteratedCHF 3.28 | 11/09/26 | 60.16%Upside | ||
| Debjit ChattopadhyayGuggenheim | BuyUpgradedCHF 4.10 | 09/23/26 | 100.20%Upside | ||
| Rick BienkowskiLadenburg Thalmann & Co. | BuyInitiatedCHF 4.92 | 08/18/26 | 140.24%Upside | ||
| Alec StranahanBank of America Securities | SellReiterated | 08/07/26 | ― | ||
| Boris PeakerJonesTrading | BuyReiteratedCHF 6.56 | 08/05/26 | 220.32%Upside | ||
| Phil NadeauTD Cowen | BuyReiterated | 08/05/26 | ― | ||
| Jonathan MillerEvercore ISI | BuyReiteratedCHF 12.29 | 05/27/26 | 500.61%Upside | ||
| Geulah LivshitsChardan Capital | BuyReiteratedCHF 3.28 | 05/05/26 | 60.16%Upside | ||
| Joon LeeUBS | HoldReiterated | 03/17/26 | ― | ||
| Brian ChengJ.P. Morgan | SellReiterated | 03/13/26 | ― | ||
| William MaughanClear Street | BuyReiteratedCHF 3.77 | 03/10/26 | 84.19%Upside | ||
| Gena WangBarclays | HoldReiteratedCHF 2.46 | 11/11/25 | 20.12%Upside |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Editas Medicine
3 Months
Success Rate4/8 ratings generated profit
50%
Average Return
+11.96%
Copying Mitchell Kapoor's trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +11.96% per trade.
1 Year
Success Rate9/15 ratings generated profit
60%
Average Return
+12.59%
Copying Phil Nadeau's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +12.59% per trade.
2 Years
Success Rate8/15 ratings generated profit
53%
Average Return
+9.81%
Copying Phil Nadeau's trades and holding each position for 2 Years would result in 53.33% of your transactions generating a profit, with an average return of +9.81% per trade.
8EM Analyst Recommendation Trends
| Rating | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|
| Strong Buy | 4 | 3 | 4 | 5 | 4 |
| Buy | 2 | 1 | 1 | 1 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 |
| Sell | 1 | 1 | 1 | 1 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 8 | 6 | 7 | 8 | 5 |
In the current month, 8EM has received 4 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. 8EM average Analyst price target in the past 3 months is 4.26.
8EM Financial Forecast
HighCHF -0.07
ConsensusCHF -0.15
LowCHF -0.19
8EM Earnings Forecast
Next quarter’s earnings estimate for 8EM is -CHF 0.15 with a range of -CHF 0.19 to -CHF 0.07. The previous quarter’s EPS was -CHF 0.12. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
HighCHF 16.5M
ConsensusCHF 5.4M
LowCHF 825K
8EM Sales Forecast
Next quarter’s sales forecast for 8EM is CHF 5.40M with a range of CHF 825.43K to CHF 16.51M. The previous quarter’s sales results were CHF 8.56M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
8EM Stock Forecast FAQ
What is CH:8EM’s average 12-month price target, according to analysts?
Based on analyst ratings, Editas Medicine’s 12-month average price target is CHF4.26.
What is CH:8EM’s upside potential, based on the analysts’ average price target?
Editas Medicine has 108.21% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Editas Medicine a Buy, Sell or Hold?
Editas Medicine has a consensus rating of Strong Buy, which is based on 4 buy ratings, 1 hold ratings and 0 sell ratings.
What is Editas Medicine’s share price target?
The average share price target for Editas Medicine is CHF4.26. This is based on 5 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is CHF4.92, and the lowest forecast is CHF3.28. The average share price target represents a 108.21% increase from the current price of CHF2.047.
What do analysts say about Editas Medicine?
Editas Medicine’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Street analysts.
How can I buy shares of Editas Medicine?
To buy shares of CH:8EM, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
